HONG KONG, Sept. 28, 2011 /PRNewswire-Asia-FirstCall/ --
Golden Meditech Holdings Limited ("Golden Meditech" or the
"Group," - 801.HK; 910801.TW), China's leading integrated healthcare
enterprise, today announced that the Group has continued to
increase its ownership in its NYSE-listed affiliate, China Cord
Blood Corporation ("CCBC," – CO.US) from the open market. As
a result of which the Group now owns 40.9% of the issued share
capital of CCBC from the previous 39.5%.
CCBC is the largest cord blood banking operator in China and is the only one with multiple
exclusive licenses including Beijing Municipal, Guangdong Province and Zhejiang Province, with approximately 20%
stake in the exclusive operator in Shandong Province.
Mr. Kam YUEN, Chairman and Chief Executive Officer of the Group,
said, "We are proud to see that CCBC has sustained strong steady
growth and profitability in its initial markets in Beijing and Guangdong while continuously deliver positive
news on new market expansions since its initial public
offering. As the founding and largest shareholder of CCBC, we
remain optimistic of CCBC's prospects in both China and Asia
Pacific and are duly confident in the capability of its
management team. We see considerable room for CCBC to further
enhance market penetration with steady growth and market
development."
Under the "one-license-per-region" regulatory framework, the
government has issued seven exclusive operating licenses thus
far. The strategic coverage of CCBC's current operation in
Beijing, Zhejiang and Guangdong has enabled it to capture key
strategic economic strongholds in the affluent eastern coastline of
China.
About Golden Meditech Holdings Limited
Golden Meditech Holdings Limited is China's leading integrated-healthcare devices
and service operator, and the first medical device enterprise that
was publicly listed outside of the PRC on the Stock Exchange of
Hong Kong Limited (HKEx) and the Taiwan Stock Exchange (TSE).
Golden Meditech is a first-mover in China, having established dominant positions
in medical devices and healthcare services markets over the years,
thanks to its strengths in innovation and market expertise and the
ability to capture emerging market opportunities. Going
forward, the Group will continue to pursue a leading position in
China's healthcare industry both
through organic growth and strategic expansion.
Investor Relations
Department
|
|
Golden Meditech Holdings
Limited
|
|
Address:
48/F, Bank of
China Tower, 1 Garden Road, Central, Hong Kong
|
|
Tel:
+852 3605 8180
|
|
Fax:
+852 3605 8181
|
|
Email:
ir@goldenmeditech.com
|
|
|
SOURCE Golden Meditech Holdings Limited